The U.S. Food and Drug Administration (FDA) has approved DENGVAXIA, a live dengue tetravalent vaccine targeting dengue serotypes 1, 2, 3, and 4 for use in children and adolescents aged six through 16 years with a laboratory confirmed history of previous dengue infection and living in dengue endemic area.
DENGVAXIA is not approved for individuals who have no prior history of dengue infection or where the history of previous infection is unknown. Individuals with no prior history of dengue are at an increased risk of developing severe dengue infection should they receive this vaccine and become infected with the dengue virus.
The CDC recommends DENGVAXIA vaccine for use in children aged nine through 16 years with a laboratory confirmed history of past dengue infection and who live in dengue endemic U.S. Territories and Freely Associated States.
Read the Package Information Insert
NVIC strongly recommends reading the vaccine manufacturer package information insert before you or your child receives any vaccine, including the dengue vaccine. Package inserts are published by drug companies making vaccines and list important information about vaccine ingredients, reported health problems (adverse events) associated with the vaccine, and directions for who should and should not get the vaccine.
A link to the dengue vaccine package insert is available below or you can ask your doctor to give you a copy of the vaccine package insert to read before your child is vaccinated. Package inserts are also available on the U.S. Food and Drug Administration’s website, as provided in the link below. It is best to ask your doctor for a copy of the package inserts for the vaccines you or your child is scheduled to receive well in advance of the vaccination appointment.
